|
|
U.S. Smoking Cessation Drug MarketPublished by: Frost & Sullivan Published: Dec. 19, 2007 - 85 Pages Table of Contents
AbstractThis Frost & Sullivan research service titled U.S. Smoking Cessation Market provides an overview of medication used to treat asthma and COPD and provides forecasts for the patient population and market revenues, along with a complete analysis of key market drivers, restraints, and challenges that are impacting this market. In this research, Frost & Sullivan's expert analysts thoroughly examine the following technologies: Zyban, Chantix, bupropion, emerging medications, and emerging vaccines.This analysis is available through our Pharmaceuticals & Biotechnology Growth Partnership Service program. With this program, clients receive industry-leading market research such as this, along with technical and econometric data and many interactive features including Analyst Inquiry Time and Client Councils. Chantix Puffs up Market for Smoking Cessation The rising population of smokers in the United States has increased concerns about health risks to both smokers and passive smokers, creating a vast market for effective smoking cessation therapies. The 2006 launch of Chantix, a revolutionary smoking cessation drug, has reversed the fortunes of this market by reviving end-user interest in it. Chantix is touted as the first blockbuster drug in this market and is expected to generate millions in revenue and expand the market at a remarkable rate. Chantix also offers an innovative and free support program called GETQUIT for buyers of this product. This type of innovation has not only increased the utilization of smoking cessation products but also inspired companies to include treatments that address the psychological aspects of smoking. Improvements in the efficacy of smoking cessation medications will greatly help improve patient compliance and encourage further drug development. Currently, the U.S. market has only two approved medications for smoking cessation. "With the increasing cost of drug and vaccine development, it is becoming more difficult for smaller companies to be able to develop products that make it through the approval process," says the analyst of this research service. "These companies need to partner with larger companies that have more resources to further develop pipeline compounds." The imminent launch of two new drugs in 2012 and 2013 and novel approaches to the treatment of smoking are expected to buoy the market. Further, scientists are also developing vaccines to address the addiction to nicotine. Introduction of Numerous Anti-smoking Laws Boosts Market for Smoking Cessation Medication The waning social acceptance of smoking is manifest in the increasing number of anti-smoking laws adopted by states and cities. These laws prohibit smoking in private workplaces, restaurants, and bars. "All 50 states and the District of Columbia have passed laws that restrict smoking to certain places," notes the analyst. "Fueling some of these restrictions is the finding that there is no safe level of exposure to secondhand smoke and that the only way to protect nonsmokers is to entirely prohibit smoking in enclosed spaces." Although extensive, these laws range from simple (requiring separate smoking sections) to very strict (prohibiting smoking in all public places). By July 2007, 15 states had implemented strict laws, while several others are starting to follow suit. In fact, another seven states have implemented similar laws and will put them into effect in 2008. Due to these numerous restricting laws, smokers are finding it difficult to light up in public. This constraint is expected to go a long way in raising demand for smoking cessation drugs. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||